<p>Lexaria Bioscience Corp.（納斯達克代碼：LEXX，LEXXW）（以下簡稱 “公司” 或 “Lexaria”），作為全球藥物遞送平台的創新者，今天宣佈完成其之前宣佈的註冊直接發行，按照納斯達克規則以市場價格發行共計 2,661,600 股普通股，每股面值為 0.001 美元，購買價格為每股 1.315 美元。此外，在同時進行的私募中，公司發行了未註冊的認股權證，允許購買最多 2,661,600 股普通股。認股權證的行使價格為每股 1.19 美元，立即可行使，並將在未註冊認股權證的轉售註冊聲明生效之日起五年內到期。</p>
<p>H.C. Wainwright &amp; Co. 擔任此次發行的獨家配售代理。</p>
<p>此次發行為公司帶來的總毛收益約為 350 萬美元，未扣除配售代理費用和公司需支付的其他發行費用。公司目前打算將此次發行的淨收益用於推進其研發工作、資助營運資金及其他一般企業用途。</p>
<p>普通股（但不包括在私募中發行的認股權證或與這些認股權證相關的普通股）是根據證券交易委員會（“SEC”）於 2025 年 1 月 30 日宣佈生效的 S-3 表格 “貨架” 註冊聲明（文件編號：333-284407）進行發行的。普通股的註冊直接發行僅通過招股説明書進行，包括構成有效註冊聲明一部分的招股説明書補充。與註冊直接發行相關的招股説明書補充及招股説明書已向 SEC 提交，並可在 SEC 網站 www.sec.gov 上獲取。與註冊直接發行相關的招股説明書補充及招股説明書的電子版也可通過聯繫 H.C. Wainwright &amp; Co., LLC，地址為紐約公園大道 430 號，3 樓，郵政編碼 10022，電話（212）856-5711 或電子郵件 placements@hcwco.com 獲取。</p>
<p>上述認股權證是在 1933 年證券法（“證券法”）第 4(a)(2) 條及其下的 D 條規章下的同時私募中發行的，並且與認股權證相關的普通股尚未根據證券法或適用的州證券法進行註冊。因此，除非根據有效的註冊聲明或適用的證券法註冊要求的豁免，否則這些認股權證及其相關的普通股不得在美國提供或出售。</p>
<p>本新聞稿不構成出售或招攬購買本文所述任何證券的要約，也不應在任何州或司法管轄區進行這些證券的銷售，除非在任何此類州或司法管轄區的證券法下進行註冊或資格認證之前，這種要約、招攬或銷售是合法的。</p>
<p><strong>關於 Lexaria Bioscience Corp.及 DehydraTECH</strong></p>
<p>DehydraTECH™是 Lexaria 的專利藥物遞送配方和加工平台技術，改善了多種藥物通過口服遞送進入血液的方式。DehydraTECH 已多次證明能夠提高生物吸收率，減少副作用，並更有效地穿越血腦屏障遞送某些藥物。Lexaria 運營着一個獲得許可的內部研究實驗室，並擁有強大的知識產權組合，已獲得 56 項專利，另有多項專利正在全球申請中。欲瞭解更多信息，請訪問 www.lexariabioscience.com。</p>
<p><strong>關於前瞻性聲明的警示</strong></p>
<p>本新聞稿包含前瞻性聲明。該術語在適用的證券法下有特定定義。這些聲明可能通過諸如 “預期”、“如果”、“相信”、“計劃”、“估計”、“期望”、“打算”、“可能”、“能夠”、“應該”、“將會” 等類似表達來識別。本新聞稿中的前瞻性聲明包括但不限於公司關於擬定用途的聲明，涉及從發行中獲得的收益，以及公司在開展研究計劃、獲得監管批准或補助，或從任何研究或研究中獲得積極效果或結果的能力。這些前瞻性聲明是基於當前信息反映公司最佳判斷的估計，涉及多種風險和不確定性，無法保證公司實際實現這些前瞻性聲明中披露的計劃、意圖或期望。因此，您不應對這些前瞻性聲明過度依賴。可能導致實際結果與公司估計結果顯著不同的因素包括但不限於市場和其他條件、政府監管和監管批准、管理和維持增長、負面宣傳的影響、訴訟、競爭、科學發現、專利申請和批准過程、使用 DehydraTECH 技術的產品測試或使用可能產生的不利影響、公司維持現有合作關係並實現其利益的能力、與疫情相關或其他原因導致的計劃研發的延遲或取消，以及公司在其公開公告和定期向美國證券交易委員會 EDGAR 提交的文件中不時可能識別的其他因素。公司僅為讀者提供第三方網站的鏈接，且對第三方網站信息的全面性、準確性或及時性不承擔任何責任。無法保證 Lexaria 所設想的專利及專利申請技術的任何用途、益處或優勢將以任何方式或部分實現。本聲明中的任何內容均未經過食品和藥物管理局（FDA）的評估。與 Lexaria 相關的產品並不旨在診斷、治療、治癒或預防任何疾病。本聲明中包含的任何前瞻性聲明僅在本聲明日期有效，公司明確不承擔更新本聲明中任何前瞻性聲明或鏈接到第三方網站的義務，無論是由於任何新信息、未來事件、情況變化或其他原因，法律另有要求的情況除外。</p>
<p><strong>投資者聯繫：</strong></p>
<p><strong>George Jurcic - 投資者關係負責人</strong></p>
<p>ir@lexariabioscience.com</p>
<p>電話：250-765-6424，分機 202</p>
<p><strong>來源：</strong> Lexaria Bioscience Corp.</p>
<p>查看 ACCESS Newswire 上的原始新聞稿</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExODMzOQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExODMzOQ"/></p>

LEXX

<p>Lexaria Bioscience Corp. 宣佈完成了一項 350 萬美元的註冊直接發行，按照納斯達克規則以市場價格定價。此次發行包括 2,661,600 股普通股和相同數量的未註冊認股權證。所得款項將用於研發、營運資金和一般企業用途。H.C. Wainwright & Co. 擔任此次發行的承銷商</p>

<p>Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the &#34;Company&#34; or &#34;Lexaria&#34;), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 2,661,600 shares of its common stock, par value $0.001 per share, at a purchase price of $1.315 per share. In addition, in a concurrent private placement, the Company issued unregistered warrants to purchase up to 2,661,600 shares of common stock. The warrants have an exercise price of $1.19 per share, are immediately exercisable and will expire five years from the date of the effectiveness of the resale registration statement registering the shares of common stock issuable upon exercise of the unregistered warrants.</p>
<div class="lb-trans"><p>Lexaria Bioscience Corp.（納斯達克代碼：LEXX，LEXXW）（以下簡稱 “公司” 或 “Lexaria”），作為全球藥物遞送平台的創新者，今天宣佈完成其之前宣佈的註冊直接發行，按照納斯達克規則以市場價格發行共計 2,661,600 股普通股，每股面值為 0.001 美元，購買價格為每股 1.315 美元。此外，在同時進行的私募中，公司發行了未註冊的認股權證，允許購買最多 2,661,600 股普通股。認股權證的行使價格為每股 1.19 美元，立即可行使，並將在未註冊認股權證的轉售註冊聲明生效之日起五年內到期。</p>
</div><p>H.C. Wainwright &amp; Co. acted as the exclusive placement agent for the offering.</p>
<div class="lb-trans"><p>H.C. Wainwright &amp; Co. 擔任此次發行的獨家配售代理。</p>
</div><p>The aggregate gross proceeds to the Company from the offering were approximately $3.5 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering to advance its research and development efforts, fund working capital and for other general corporate purposes.</p>
<div class="lb-trans"><p>此次發行為公司帶來的總毛收益約為 350 萬美元，未扣除配售代理費用和公司需支付的其他發行費用。公司目前打算將此次發行的淨收益用於推進其研發工作、資助營運資金及其他一般企業用途。</p>
</div><p>The shares of common stock (but not the warrants issued in the private placement or the shares of common stock underlying such warrants) were offered by the Company pursuant to a &#34;shelf&#34; registration statement on Form S-3 (File No. 333-284407) that was declared effective by the Securities and Exchange Commission (the &#34;SEC&#34;) on January 30, 2025. The registered direct offering of the shares of common stock was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating to the securities being offered in the registered direct offering were filed with the SEC and are available at the SEC's website at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the registered direct offering may also be obtained by contacting H.C. Wainwright &amp; Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (212) 856-5711 or e-mail at placements@hcwco.com.</p>
<div class="lb-trans"><p>普通股（但不包括在私募中發行的認股權證或與這些認股權證相關的普通股）是根據證券交易委員會（“SEC”）於 2025 年 1 月 30 日宣佈生效的 S-3 表格 “貨架” 註冊聲明（文件編號：333-284407）進行發行的。普通股的註冊直接發行僅通過招股説明書進行，包括構成有效註冊聲明一部分的招股説明書補充。與註冊直接發行相關的招股説明書補充及招股説明書已向 SEC 提交，並可在 SEC 網站 www.sec.gov 上獲取。與註冊直接發行相關的招股説明書補充及招股説明書的電子版也可通過聯繫 H.C. Wainwright &amp; Co., LLC，地址為紐約公園大道 430 號，3 樓，郵政編碼 10022，電話（212）856-5711 或電子郵件 placements@hcwco.com 獲取。</p>
</div><p>The warrants described above were issued in a concurrent private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &#34;Securities Act&#34;), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.</p>
<div class="lb-trans"><p>上述認股權證是在 1933 年證券法（“證券法”）第 4(a)(2) 條及其下的 D 條規章下的同時私募中發行的，並且與認股權證相關的普通股尚未根據證券法或適用的州證券法進行註冊。因此，除非根據有效的註冊聲明或適用的證券法註冊要求的豁免，否則這些認股權證及其相關的普通股不得在美國提供或出售。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售或招攬購買本文所述任何證券的要約，也不應在任何州或司法管轄區進行這些證券的銷售，除非在任何此類州或司法管轄區的證券法下進行註冊或資格認證之前，這種要約、招攬或銷售是合法的。</p>
</div><p><strong>About Lexaria Bioscience Corp. &amp; DehydraTECH</strong></p>
<div class="lb-trans"><p><strong>關於 Lexaria Bioscience Corp.及 DehydraTECH</strong></p>
</div><p>DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 56 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.</p>
<div class="lb-trans"><p>DehydraTECH™是 Lexaria 的專利藥物遞送配方和加工平台技術，改善了多種藥物通過口服遞送進入血液的方式。DehydraTECH 已多次證明能夠提高生物吸收率，減少副作用，並更有效地穿越血腦屏障遞送某些藥物。Lexaria 運營着一個獲得許可的內部研究實驗室，並擁有強大的知識產權組合，已獲得 56 項專利，另有多項專利正在全球申請中。欲瞭解更多信息，請訪問 www.lexariabioscience.com。</p>
</div><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p>
<div class="lb-trans"><p><strong>關於前瞻性聲明的警示</strong></p>
</div><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as &#34;anticipate,&#34; &#34;if,&#34; &#34;believe,&#34; &#34;plan,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;could,&#34; &#34;should,&#34; &#34;will,&#34; and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&amp;D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p>
<div class="lb-trans"><p>本新聞稿包含前瞻性聲明。該術語在適用的證券法下有特定定義。這些聲明可能通過諸如 “預期”、“如果”、“相信”、“計劃”、“估計”、“期望”、“打算”、“可能”、“能夠”、“應該”、“將會” 等類似表達來識別。本新聞稿中的前瞻性聲明包括但不限於公司關於擬定用途的聲明，涉及從發行中獲得的收益，以及公司在開展研究計劃、獲得監管批准或補助，或從任何研究或研究中獲得積極效果或結果的能力。這些前瞻性聲明是基於當前信息反映公司最佳判斷的估計，涉及多種風險和不確定性，無法保證公司實際實現這些前瞻性聲明中披露的計劃、意圖或期望。因此，您不應對這些前瞻性聲明過度依賴。可能導致實際結果與公司估計結果顯著不同的因素包括但不限於市場和其他條件、政府監管和監管批准、管理和維持增長、負面宣傳的影響、訴訟、競爭、科學發現、專利申請和批准過程、使用 DehydraTECH 技術的產品測試或使用可能產生的不利影響、公司維持現有合作關係並實現其利益的能力、與疫情相關或其他原因導致的計劃研發的延遲或取消，以及公司在其公開公告和定期向美國證券交易委員會 EDGAR 提交的文件中不時可能識別的其他因素。公司僅為讀者提供第三方網站的鏈接，且對第三方網站信息的全面性、準確性或及時性不承擔任何責任。無法保證 Lexaria 所設想的專利及專利申請技術的任何用途、益處或優勢將以任何方式或部分實現。本聲明中的任何內容均未經過食品和藥物管理局（FDA）的評估。與 Lexaria 相關的產品並不旨在診斷、治療、治癒或預防任何疾病。本聲明中包含的任何前瞻性聲明僅在本聲明日期有效，公司明確不承擔更新本聲明中任何前瞻性聲明或鏈接到第三方網站的義務，無論是由於任何新信息、未來事件、情況變化或其他原因，法律另有要求的情況除外。</p>
</div><p><strong>INVESTOR CONTACT:</strong></p>
<div class="lb-trans"><p><strong>投資者聯繫：</strong></p>
</div><p><strong>George Jurcic - Head of Investor Relations</strong></p>
<div class="lb-trans"><p><strong>George Jurcic - 投資者關係負責人</strong></p>
</div><p>ir@lexariabioscience.com</p>
<div class="lb-trans"><p>ir@lexariabioscience.com</p>
</div><p>Phone: 250-765-6424, ext 202</p>
<div class="lb-trans"><p>電話：250-765-6424，分機 202</p>
</div><p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p>
<div class="lb-trans"><p><strong>來源：</strong> Lexaria Bioscience Corp.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新聞稿</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExODMzOQ" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1118339"/></p>

Lexaria Bioscience Corp.宣佈根據納斯達克規則以市場價格完成 350 萬美元的註冊直接發行 | LEXX 股票新聞